Untangling the ErbB signalling network View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-02

AUTHORS

Yosef Yarden, Mark X. Sliwkowski

ABSTRACT

Key Points The four ErbB receptors and their many neuregulins and EGF-like ligands form a layered signalling network. The network structure allows the diversification, tuning and robustness of cell-to-cell signalling. The network evolved from a simple signalling module that controls inductive morphogenesis in invertebrates. In mammals, specific ligands and their respective homo- or heterodimeric ErbB complexes specify different cell lineages. Oncogenic animal viruses harness the network through diverse molecular processes that promote ErbB signalling or prevent it from being switched off. Autocrine loops, mutant ErbB1 molecules and enhanced expression of ErbB receptors are frequently observed in human cancers of epithelial and neuronal origins. Most frequent is overexpression of ErbB2, a ligandless co-receptor that amplifies ErbB signalling. Current attempts to block the network in human disease include small-molecule inhibitors of tyrosine kinases and chaperones, and various gene-therapy strategies. But immunotherapy directed at ErbB2 is already widely used, in combination with chemotherapy, to inhibit metastasizing breast cancers. Future pharmacological advances and deeper understanding of the network will allow selective inhibition or activation of its many routes, with the aim of curing neuronal and skin disorders, as well as cancer. More... »

PAGES

127-137

References to SciGraph publications

  • 1999-12. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF in NATURE
  • 1996-10. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation in NATURE
  • 1997-12-18. Neuregulin-β induces expression of an NMDA-receptor subunit in NATURE
  • 1998-07-30. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation in ONCOGENE
  • 2000-04. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets in NATURE MEDICINE
  • 2000-02-22. c-erbB-4 protein expression in human breast cancer in BRITISH JOURNAL OF CANCER
  • 1995-07. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor in NATURE
  • 1998-05. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells in NATURE
  • 1998-01. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. in JOURNAL OF NEUROVIROLOGY
  • 1997-02-06. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer in ONCOGENE
  • 1999-04-22. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase in ONCOGENE
  • 1997-10. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor in NATURE
  • 2000-02-17. Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization in ONCOGENE
  • 1997-11. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone in NATURE
  • 2000-06-08. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor in NATURE CELL BIOLOGY
  • 1995-08. Inhibition of Drosophila EGF receptor activation by the secreted protein Argos in NATURE
  • Journal

    TITLE

    Nature Reviews Molecular Cell Biology

    ISSUE

    2

    VOLUME

    2

    Related Patents

  • Anti-Erbb Antibodies And Methods Of Use Thereof
  • Her2 Diagnostic Methods
  • Azaindazole Compounds As Inhibitors Of T790m Containing Egfr Mutants
  • Specific Binding Proteins And Uses Thereof
  • Detection Of Protein To Protein Interactions
  • Anti-Her Antibodies
  • Development Of Masked Therapeutic Antibodies To Limit Off-Target Effects; Application To Anti-Egfr Antibodies
  • 2-Benzopyrazinyl-N-Heteroaryl-2-Phenyl-Acetamide Compounds
  • Antibodies With Increased Affinity For The Epidermal Growth Factor Receptor And Fragments Derived Therefrom
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Benzimidazole Derivatives As Erbb Tyrosine Kinase Inhibitors For The Treatment Of Cancer
  • Combination Therapy Using Anti-Egfr And Anti-Her2 Antibodies
  • Compositions And Methods For Treating Heart Failure
  • Selective Grp94 Inhibitors And Uses Thereof
  • Binding Molecules Specific For Her3 And Uses Thereof
  • Pharmaceutical Compositions For The Treatment Of Tumours That Express Egfr And Ganglioside N-Glycolyl Gm3 (Neugcgm3)
  • Benzimidazole Derivatives As Erbb Tyrosine Kinase Inhibitors For The Treatment Of Cancer
  • Uses Of Neuregulin In Preventing, Treating Or Delaying Ventricular Arrhythmia, And Composition Thereof
  • Gene Expression Markers Of Tumor Resistance To Her2 Inhibitor Treatment
  • Extending Time To Disease Progression Or Survival In Cancer Patients
  • Benzimidazole Derivatives As Erbb Tyrosine Kinase Inhibitors For The Treatment Of Cancer
  • Molecular Display System
  • Specific Binding Proteins And Uses Thereof
  • Methods And Compositions For Treating Metastatic Breast Cancer And Other Cancers In The Brain
  • Development Of Masked Therapeutic Antibodies To Limit Off-Target Effects
  • Cell Analysis
  • Methods Of Determining Patient Response By Measurement Of Her-3
  • Specific Binding Proteins And Uses Thereof
  • Anti-Her2 Antibodies And Compositions
  • C-Met Modulators And Methods Of Use
  • Specific Binding Proteins And Uses Thereof
  • Use Of Anti-Egfr Antibodies In Treatment Of Egfr Mutant Mediated Disease
  • Specific Binding Proteins And Uses Thereof
  • Antibodies Against Cxcr4 And Methods Of Use Thereof
  • Combinatorial Therapy For Protein Signaling Diseases
  • C-Met Modulators And Methods Of Use
  • Methods Of Making And Using Multispecific Antibody Panels And Antibody Analog Panels
  • Benzimidazoles For Use In The Treatment Of Cancer And Inflammatory Diseases
  • C-Met Modulators And Method Of Use
  • Her-2 Binding Antagonists
  • C-Met Modulators And Method Of Use
  • Development Of Masked Therapeutic Antibodies To Limit Off-Target Effects
  • Human Serum Albumin Linkers And Conjugates Thereof
  • Non-Antagonistic Egfr-Binding Molecules And Immunoconjugates Thereof
  • Methods For Treating Sarcopenia And Frailty
  • Her-2 Binding Antagonists
  • Selective Grp94 Inhibitors And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Formula Of Neuregulin Preparation
  • Methods Of Sensitizing A Patient With Glioma To A Therapeutic Agent By Administering Small Hairpin Rna Targeting Pdz-Rhogef
  • Substituted Tricyclic Compounds And Methods Of Use Thereof
  • Egfr-Binding Molecules And Immunoconjugates Thereof
  • Methods Of Determining Patient Response By Measurement Of Her-3
  • Development Of Masked Therapeutic Antibodies To Limit Off-Target Effects: Application To Anti-Egfr Antibodies
  • Binding Molecules Specific For Her3 And Uses Thereof
  • Materials And Methods For Modulating Cell Motility
  • Binding Molecules Specific For Her3 And Uses Thereof
  • Inhibiting Cell Growth And Metastasis And Treat Cancer ; A Disintegrin And Metalloproteinase With Thrombospondin Motifs (Adamts)
  • Immunoglobulin Composition Specific Epidermal Growth Factor Receptor For Use In Treatment Of Cell Proliferative And Autoimmune Diseases; Immunotherapy; Tissue Targeted Therapy
  • Fixed Dosing Of Her Antibodies
  • Methods For Predicting Treatment Response Based On The Expression Profiles Of Protein And Transcription Biomarkers
  • Antibodies To Egf Receptor Epitope Peptides And Uses Thereof
  • Combinatorial Therapy For Protein Signaling Diseases
  • Binding Molecules Specific For Her3 And Uses Thereof
  • Compositions Of And Methods Of Using Ligand Dimers
  • Method Of Treatment Of Tumors That Are Resistant To Egfr Antibody Therapies By Egfr Antibody Cytotoxic Agent Conjugate
  • Combination Therapy With An Anti-Her2 Antibody-Drug Conjugate And A Bcl-2 Inhibitor
  • Development Of Masked Therapeutic Antibodies To Limit Off-Target Effects
  • Benzimidazoles For Use In The Treatment Of Cancer And Inflammatory Diseases
  • Growth Factor Which Acts Through Erbb-4 Rtk
  • Exosomes With Drug Trapped And Aptamer Attached To The Surface And Methods Of Thereof
  • Her-3 Antibodies And Methods Of Use
  • N-(4-{[7-{[3-(Diethylamino)Propyl] Oxy}-6-(Methyloxy) Quinazolin-4-Yl]Oxy}-3- Fluorophenyl)-N'-(4- Fluorophenyl) Cyclopropane-1,1-Dicarboxamide; For Modulating Protein Kinase Enzymatic Activity For Modulating Cell Activities Such As Proliferation, Differentiation, Programmed Cell Death
  • Erbb Receptor-Derived Peptide Fragments
  • Extended Release Of Neuregulin For Treating Heart Failure
  • Treatment With Anti-Vegf Antibodies
  • Methods For Cardioprotection And Cardioregeneration With Dimers Of Egf Family Ligands
  • Benzimidazole Derivatives As Erbb Tyrosine Kinase Inhibitors For The Treatment Of Cancer
  • Scanning Phase Intracavity Nanoscope
  • Use Of Subcellular Localization Profiles As Prognostic Or Predictive Indicators
  • Methods Of Producing Antibodies Specific For P95
  • Benzimidazole Derivatives As Erbb Tyrosine Kinase Inhibitors For The Treatment Of Cancer
  • Stable Polypeptide Formulations
  • Fibrinogen Alpha And Hemoglobin Polypeptides As Cancer Markers
  • Process
  • Epidermal Growth Factor Receptor-Derived Peptides
  • Binding Proteins Specific For Egfr Expressed On Tumor And Uses Thereof
  • Methods Of Treating Her2-Positive Metastatic Breast Cancer
  • Combination Therapies Comprising Anti-Erbb3 Agents
  • Methods Of Determining Patient Response By Measurement Of Her-3 And P95
  • Subcutaneous Her2 Antibody Formulations
  • Monoclonal Antibody 175 Targeting The Egf Receptor And Derivatives And Uses Thereof
  • Methods And Compositions Of Neuregulins For Preventing, Treating Or Delaying Preserved Ejection Fraction Cardiac Failure
  • Peptide-Dna Chimeras For Treatment Of Her Overexpressing Cancers
  • Detection Of Protein To Protein Interactions
  • C-Met Modulators And Method Of Use
  • Egfr-Binding Molecules And Immunoconjugates Thereof
  • Substituted Isoindole Allosteric Egfr Inhibitors
  • Bispecific Antibodies Directed Against Ox40 And A Tumor-Associated Antigen
  • Egf Receptor Epitope Peptides And Uses Thereof
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Measuring Receptor Homodimerization
  • Methods Used To Treat Cancer
  • Antibody-Based Constructs Directed Against Tyrosine Kinase Receptors
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/35052073

    DOI

    http://dx.doi.org/10.1038/35052073

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1053565592

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/11252954


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, ErbB-2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel", 
              "id": "http://www.grid.ac/institutes/grid.13992.30", 
              "name": [
                "Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yarden", 
            "givenName": "Yosef", 
            "id": "sg:person.01336614556.63", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336614556.63"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular Oncology, Genentech Inc., 94080, South San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.418158.1", 
              "name": [
                "Department of Molecular Oncology, Genentech Inc., 94080, South San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sliwkowski", 
            "givenName": "Mark X.", 
            "id": "sg:person.01326463516.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326463516.11"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.onc.1203410", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032633934", 
              "https://doi.org/10.1038/sj.onc.1203410"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/376337a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022886679", 
              "https://doi.org/10.1038/376337a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/376699a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017864713", 
              "https://doi.org/10.1038/376699a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/74704", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000366392", 
              "https://doi.org/10.1038/74704"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1201954", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001045998", 
              "https://doi.org/10.1038/sj.onc.1201954"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1202612", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018058051", 
              "https://doi.org/10.1038/sj.onc.1202612"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/36369", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001299349", 
              "https://doi.org/10.1038/36369"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/39593", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040285658", 
              "https://doi.org/10.1038/39593"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/37795", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047131904", 
              "https://doi.org/10.1038/37795"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/383547a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029882154", 
              "https://doi.org/10.1038/383547a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.3109/13550289809114515", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1070986052", 
              "https://doi.org/10.3109/13550289809114515"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1200861", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020139253", 
              "https://doi.org/10.1038/sj.onc.1200861"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35017038", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035059200", 
              "https://doi.org/10.1038/35017038"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/47260", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026108629", 
              "https://doi.org/10.1038/47260"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/30012", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040525987", 
              "https://doi.org/10.1038/30012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1054/bjoc.1999.1057", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034062010", 
              "https://doi.org/10.1054/bjoc.1999.1057"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2001-02", 
        "datePublishedReg": "2001-02-01", 
        "description": "Key Points The four ErbB receptors and their many neuregulins and EGF-like ligands form a layered signalling network. The network structure allows the diversification, tuning and robustness of cell-to-cell signalling.  The network evolved from a simple signalling module that controls inductive morphogenesis in invertebrates. In mammals, specific ligands and their respective homo- or heterodimeric ErbB complexes specify different cell lineages.  Oncogenic animal viruses harness the network through diverse molecular processes that promote ErbB signalling or prevent it from being switched off.  Autocrine loops, mutant ErbB1 molecules and enhanced expression of ErbB receptors are frequently observed in human cancers of epithelial and neuronal origins. Most frequent is overexpression of ErbB2, a ligandless co-receptor that amplifies ErbB signalling.  Current attempts to block the network in human disease include small-molecule inhibitors of tyrosine kinases and chaperones, and various gene-therapy strategies. But immunotherapy directed at ErbB2 is already widely used, in combination with chemotherapy, to inhibit metastasizing breast cancers.  Future pharmacological advances and deeper understanding of the network will allow selective inhibition or activation of its many routes, with the aim of curing neuronal and skin disorders, as well as cancer.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/35052073", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1023609", 
            "issn": [
              "1471-0072", 
              "1471-0080"
            ], 
            "name": "Nature Reviews Molecular Cell Biology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "diverse molecular processes", 
          "ErbB receptors", 
          "robustness of cells", 
          "different cell lineages", 
          "EGF-like ligands", 
          "small molecule inhibitors", 
          "cell signaling", 
          "cell lineages", 
          "animal viruses", 
          "tyrosine kinase", 
          "molecular processes", 
          "human diseases", 
          "human cancers", 
          "overexpression of ErbB2", 
          "ErbB", 
          "autocrine loop", 
          "enhanced expression", 
          "specific ligands", 
          "gene therapy strategies", 
          "selective inhibition", 
          "ErbB2", 
          "neuronal origin", 
          "chaperones", 
          "invertebrates", 
          "morphogenesis", 
          "lineages", 
          "mammals", 
          "kinase", 
          "receptors", 
          "signaling", 
          "overexpression", 
          "diversification", 
          "neuregulin", 
          "expression", 
          "ligands", 
          "deeper understanding", 
          "cells", 
          "activation", 
          "inhibitors", 
          "cancer", 
          "complexes", 
          "inhibition", 
          "virus", 
          "molecules", 
          "skin disorders", 
          "current attempts", 
          "origin", 
          "homo", 
          "breast cancer", 
          "understanding", 
          "key", 
          "loop", 
          "advances", 
          "respective HOMO", 
          "pharmacological advances", 
          "structure", 
          "network", 
          "disease", 
          "combination", 
          "process", 
          "strategies", 
          "disorders", 
          "network structure", 
          "module", 
          "attempt", 
          "route", 
          "tuning", 
          "aim", 
          "ligandless", 
          "immunotherapy", 
          "chemotherapy", 
          "robustness"
        ], 
        "name": "Untangling the ErbB signalling network", 
        "pagination": "127-137", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1053565592"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/35052073"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "11252954"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/35052073", 
          "https://app.dimensions.ai/details/publication/pub.1053565592"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:48", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_331.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/35052073"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/35052073'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/35052073'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/35052073'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/35052073'


     

    This table displays all metadata directly associated to this object as RDF triples.

    223 TRIPLES      21 PREDICATES      118 URIs      94 LITERALS      11 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/35052073 schema:about N772015b8d63d4e70b64c119920266916
    2 N8bd8dcb42d6342569c2c6e5279c13e26
    3 Na102bf4961074b0bb48909f26ce5a91a
    4 Nebb64131b3a2406982bee2c2024a6f24
    5 anzsrc-for:06
    6 anzsrc-for:0601
    7 schema:author N1fceb1cd654f4a539c670ac2c6b0e714
    8 schema:citation sg:pub.10.1038/30012
    9 sg:pub.10.1038/35017038
    10 sg:pub.10.1038/36369
    11 sg:pub.10.1038/376337a0
    12 sg:pub.10.1038/376699a0
    13 sg:pub.10.1038/37795
    14 sg:pub.10.1038/383547a0
    15 sg:pub.10.1038/39593
    16 sg:pub.10.1038/47260
    17 sg:pub.10.1038/74704
    18 sg:pub.10.1038/sj.onc.1200861
    19 sg:pub.10.1038/sj.onc.1201954
    20 sg:pub.10.1038/sj.onc.1202612
    21 sg:pub.10.1038/sj.onc.1203410
    22 sg:pub.10.1054/bjoc.1999.1057
    23 sg:pub.10.3109/13550289809114515
    24 schema:datePublished 2001-02
    25 schema:datePublishedReg 2001-02-01
    26 schema:description Key Points The four ErbB receptors and their many neuregulins and EGF-like ligands form a layered signalling network. The network structure allows the diversification, tuning and robustness of cell-to-cell signalling. The network evolved from a simple signalling module that controls inductive morphogenesis in invertebrates. In mammals, specific ligands and their respective homo- or heterodimeric ErbB complexes specify different cell lineages. Oncogenic animal viruses harness the network through diverse molecular processes that promote ErbB signalling or prevent it from being switched off. Autocrine loops, mutant ErbB1 molecules and enhanced expression of ErbB receptors are frequently observed in human cancers of epithelial and neuronal origins. Most frequent is overexpression of ErbB2, a ligandless co-receptor that amplifies ErbB signalling. Current attempts to block the network in human disease include small-molecule inhibitors of tyrosine kinases and chaperones, and various gene-therapy strategies. But immunotherapy directed at ErbB2 is already widely used, in combination with chemotherapy, to inhibit metastasizing breast cancers. Future pharmacological advances and deeper understanding of the network will allow selective inhibition or activation of its many routes, with the aim of curing neuronal and skin disorders, as well as cancer.
    27 schema:genre article
    28 schema:isAccessibleForFree false
    29 schema:isPartOf N240e9d9995d046ac9be089599d763bf6
    30 Nc80032e07aae44729af192d6b7888606
    31 sg:journal.1023609
    32 schema:keywords EGF-like ligands
    33 ErbB
    34 ErbB receptors
    35 ErbB2
    36 activation
    37 advances
    38 aim
    39 animal viruses
    40 attempt
    41 autocrine loop
    42 breast cancer
    43 cancer
    44 cell lineages
    45 cell signaling
    46 cells
    47 chaperones
    48 chemotherapy
    49 combination
    50 complexes
    51 current attempts
    52 deeper understanding
    53 different cell lineages
    54 disease
    55 disorders
    56 diverse molecular processes
    57 diversification
    58 enhanced expression
    59 expression
    60 gene therapy strategies
    61 homo
    62 human cancers
    63 human diseases
    64 immunotherapy
    65 inhibition
    66 inhibitors
    67 invertebrates
    68 key
    69 kinase
    70 ligandless
    71 ligands
    72 lineages
    73 loop
    74 mammals
    75 module
    76 molecular processes
    77 molecules
    78 morphogenesis
    79 network
    80 network structure
    81 neuregulin
    82 neuronal origin
    83 origin
    84 overexpression
    85 overexpression of ErbB2
    86 pharmacological advances
    87 process
    88 receptors
    89 respective HOMO
    90 robustness
    91 robustness of cells
    92 route
    93 selective inhibition
    94 signaling
    95 skin disorders
    96 small molecule inhibitors
    97 specific ligands
    98 strategies
    99 structure
    100 tuning
    101 tyrosine kinase
    102 understanding
    103 virus
    104 schema:name Untangling the ErbB signalling network
    105 schema:pagination 127-137
    106 schema:productId N402793e422634f25a270ba4d007cc7c6
    107 N747665ca3e984b9c98d2206807f016d0
    108 Ne26fee12b02f4afe84fb5a871fd24722
    109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565592
    110 https://doi.org/10.1038/35052073
    111 schema:sdDatePublished 2022-11-24T20:48
    112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    113 schema:sdPublisher N0ad3c4270a1647e0b3a94428295083ef
    114 schema:url https://doi.org/10.1038/35052073
    115 sgo:license sg:explorer/license/
    116 sgo:sdDataset articles
    117 rdf:type schema:ScholarlyArticle
    118 N0ad3c4270a1647e0b3a94428295083ef schema:name Springer Nature - SN SciGraph project
    119 rdf:type schema:Organization
    120 N1fceb1cd654f4a539c670ac2c6b0e714 rdf:first sg:person.01336614556.63
    121 rdf:rest N8d00f11906414f8999204f2a22514512
    122 N240e9d9995d046ac9be089599d763bf6 schema:issueNumber 2
    123 rdf:type schema:PublicationIssue
    124 N402793e422634f25a270ba4d007cc7c6 schema:name doi
    125 schema:value 10.1038/35052073
    126 rdf:type schema:PropertyValue
    127 N747665ca3e984b9c98d2206807f016d0 schema:name pubmed_id
    128 schema:value 11252954
    129 rdf:type schema:PropertyValue
    130 N772015b8d63d4e70b64c119920266916 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Animals
    132 rdf:type schema:DefinedTerm
    133 N8bd8dcb42d6342569c2c6e5279c13e26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Signal Transduction
    135 rdf:type schema:DefinedTerm
    136 N8d00f11906414f8999204f2a22514512 rdf:first sg:person.01326463516.11
    137 rdf:rest rdf:nil
    138 Na102bf4961074b0bb48909f26ce5a91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Neoplasms
    140 rdf:type schema:DefinedTerm
    141 Nc80032e07aae44729af192d6b7888606 schema:volumeNumber 2
    142 rdf:type schema:PublicationVolume
    143 Ne26fee12b02f4afe84fb5a871fd24722 schema:name dimensions_id
    144 schema:value pub.1053565592
    145 rdf:type schema:PropertyValue
    146 Nebb64131b3a2406982bee2c2024a6f24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Receptor, ErbB-2
    148 rdf:type schema:DefinedTerm
    149 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    150 schema:name Biological Sciences
    151 rdf:type schema:DefinedTerm
    152 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Biochemistry and Cell Biology
    154 rdf:type schema:DefinedTerm
    155 sg:journal.1023609 schema:issn 1471-0072
    156 1471-0080
    157 schema:name Nature Reviews Molecular Cell Biology
    158 schema:publisher Springer Nature
    159 rdf:type schema:Periodical
    160 sg:person.01326463516.11 schema:affiliation grid-institutes:grid.418158.1
    161 schema:familyName Sliwkowski
    162 schema:givenName Mark X.
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326463516.11
    164 rdf:type schema:Person
    165 sg:person.01336614556.63 schema:affiliation grid-institutes:grid.13992.30
    166 schema:familyName Yarden
    167 schema:givenName Yosef
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336614556.63
    169 rdf:type schema:Person
    170 sg:pub.10.1038/30012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040525987
    171 https://doi.org/10.1038/30012
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1038/35017038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035059200
    174 https://doi.org/10.1038/35017038
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1038/36369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001299349
    177 https://doi.org/10.1038/36369
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1038/376337a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022886679
    180 https://doi.org/10.1038/376337a0
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1038/376699a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017864713
    183 https://doi.org/10.1038/376699a0
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1038/37795 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047131904
    186 https://doi.org/10.1038/37795
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1038/383547a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029882154
    189 https://doi.org/10.1038/383547a0
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1038/39593 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040285658
    192 https://doi.org/10.1038/39593
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1038/47260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026108629
    195 https://doi.org/10.1038/47260
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1038/74704 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000366392
    198 https://doi.org/10.1038/74704
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1038/sj.onc.1200861 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020139253
    201 https://doi.org/10.1038/sj.onc.1200861
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1038/sj.onc.1201954 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001045998
    204 https://doi.org/10.1038/sj.onc.1201954
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1038/sj.onc.1202612 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018058051
    207 https://doi.org/10.1038/sj.onc.1202612
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1038/sj.onc.1203410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032633934
    210 https://doi.org/10.1038/sj.onc.1203410
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1054/bjoc.1999.1057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034062010
    213 https://doi.org/10.1054/bjoc.1999.1057
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.3109/13550289809114515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070986052
    216 https://doi.org/10.3109/13550289809114515
    217 rdf:type schema:CreativeWork
    218 grid-institutes:grid.13992.30 schema:alternateName Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
    219 schema:name Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
    220 rdf:type schema:Organization
    221 grid-institutes:grid.418158.1 schema:alternateName Department of Molecular Oncology, Genentech Inc., 94080, South San Francisco, California, USA
    222 schema:name Department of Molecular Oncology, Genentech Inc., 94080, South San Francisco, California, USA
    223 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...